New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

New York State Common Retirement Fund lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,023 shares of the company’s stock after selling 2,488 shares during the quarter. New York State Common Retirement Fund owned approximately 0.05% of Enliven Therapeutics worth $563,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after purchasing an additional 1,275 shares during the period. Verition Fund Management LLC acquired a new stake in Enliven Therapeutics during the third quarter worth approximately $271,000. SG Americas Securities LLC increased its stake in Enliven Therapeutics by 66.1% during the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock worth $374,000 after acquiring an additional 6,616 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after acquiring an additional 3,518 shares in the last quarter. Finally, Quest Partners LLC lifted its position in shares of Enliven Therapeutics by 1,226.4% during the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after acquiring an additional 19,525 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Up 1.5 %

Shares of ELVN opened at $19.92 on Wednesday. The stock has a 50 day moving average of $21.93 and a 200 day moving average of $23.94. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The company has a market capitalization of $973.27 million, a price-to-earnings ratio of -10.48 and a beta of 1.03.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $265,330. The trade was a 20.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at approximately $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,117 shares of company stock worth $949,435. 29.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ELVN. BTIG Research started coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.